Elixxer Stock Performance
| ELXR Stock | CAD 1.15 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Elixxer are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Elixxer has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Elixxer is not utilizing all of its potentials. The recent stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
Last Split Factor 1:100 | Dividend Date 2016-07-19 | Last Split Date 2022-02-10 |
1 | Elixirr Acquires Hypothesis - FinSMEs | 10/21/2024 |
2 | Elixir Capitals Stock Reaches 52-Week High, Outperforms Sector with Impressive Gains - MarketsMojo | 12/02/2024 |
3 | Elixxer Announces Appointment of Fiona Fitzmaurice as Chief Financial Officer - Yahoo Finance | 12/12/2024 |
| Begin Period Cash Flow | 191.5 K | |
| Free Cash Flow | -2.4 M |
Elixxer |
Elixxer Relative Risk vs. Return Landscape
If you would invest 115.00 in Elixxer on September 22, 2024 and sell it today you would earn a total of 0.00 from holding Elixxer or generate 0.0% return on investment over 90 days. Elixxer is producing return of less than zero assuming 0.0% volatility of returns over the 90 days investment horizon. Simply put, 0% of all stocks have less volatile historical return distribution than Elixxer, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Elixxer Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Elixxer's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Elixxer, and traders can use it to determine the average amount a Elixxer's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ELXR |
Based on monthly moving average Elixxer is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Elixxer by adding Elixxer to a well-diversified portfolio.
Elixxer Fundamentals Growth
Elixxer Stock prices reflect investors' perceptions of the future prospects and financial health of Elixxer, and Elixxer fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Elixxer Stock performance.
| Return On Equity | -10.14 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 21.92 M | ||||
| Shares Outstanding | 11.34 M | ||||
| Price To Book | 2.67 X | ||||
| Price To Sales | 767,774 X | ||||
| Revenue | 82.13 K | ||||
| Gross Profit | 42.41 K | ||||
| EBITDA | (2.5 M) | ||||
| Net Income | (6.17 M) | ||||
| Cash And Equivalents | 969.92 K | ||||
| Total Debt | 4.41 M | ||||
| Debt To Equity | 1.96 % | ||||
| Book Value Per Share | (0.76) X | ||||
| Cash Flow From Operations | (2.35 M) | ||||
| Earnings Per Share | (1.02) X | ||||
| Total Asset | 5.37 M | ||||
| Retained Earnings | (80.5 M) | ||||
About Elixxer Performance
Evaluating Elixxer's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Elixxer has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Elixxer has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. ELIXXER is traded on Commodity Exchange in Exotistan.Things to note about Elixxer performance evaluation
Checking the ongoing alerts about Elixxer for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Elixxer help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Elixxer generated a negative expected return over the last 90 days | |
| Elixxer may become a speculative penny stock | |
| Elixxer has a very high chance of going through financial distress in the upcoming years | |
| Elixxer has accumulated 4.41 M in total debt with debt to equity ratio (D/E) of 1.96, which is about average as compared to similar companies. Elixxer has a current ratio of 0.06, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Elixxer until it has trouble settling it off, either with new capital or with free cash flow. So, Elixxer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Elixxer sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Elixxer to invest in growth at high rates of return. When we think about Elixxer's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 82.13 K. Net Loss for the year was (6.17 M) with profit before overhead, payroll, taxes, and interest of 42.41 K. | |
| Elixxer has accumulated about 969.92 K in cash with (2.35 M) of positive cash flow from operations. | |
| Latest headline from news.google.com: Elixxer Announces Appointment of Fiona Fitzmaurice as Chief Financial Officer - Yahoo Finance |
- Analyzing Elixxer's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Elixxer's stock is overvalued or undervalued compared to its peers.
- Examining Elixxer's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Elixxer's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Elixxer's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Elixxer's stock. These opinions can provide insight into Elixxer's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Elixxer Stock Analysis
When running Elixxer's price analysis, check to measure Elixxer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elixxer is operating at the current time. Most of Elixxer's value examination focuses on studying past and present price action to predict the probability of Elixxer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elixxer's price. Additionally, you may evaluate how the addition of Elixxer to your portfolios can decrease your overall portfolio volatility.